Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic ...

Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON)FDA Breakthrough Therapy and EMA PRIME desi ...

New post-hoc analysis of OCT scans on GCIPL and analysis of responders with improvement of 15 or 30-letter on low-contrast visual acuity (LCVA) from the Phase 2 ACUITY trial with Privosegtor, to be ...

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention ...

The FDA agreed that the design of a Phase 3 trial testing privosegtor in optic neuritis could support a future approval ...

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Eric's career includes extensive work in both public and corporate accounting with ...

Transient vision loss is temporary vision loss lasting from seconds to less than 24 hours that can affect one or both eyes. It can indicate vascular health conditions, including an impending stroke.

Dry eye syndrome can cause several side effects, some of which can affect your vision. It’s important to seek treatment before the condition becomes severe, as it can cause permanent damage. Dry eye ...

Lorraine Roberte is an insurance writer for Investopedia. As a personal finance writer, her expertise includes money management and insurance-related topics. She has written hundreds of reviews of ...